Publications Print Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928 Epub 2024 Aug 13 View PubMed Smith KER, Pritzl SL, Yu W, Bara I, Thanarajasingam G, Kaul MD, Williams KA, Dueck AC, Mansfield AS. The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab. JTO Clin Res Rep. 2023 Dec; 4 (12):100611 Epub 2023 Nov 23 View PubMed Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, Dudek AZ, Yan Y, Dimou A, Markovic SN, Federspiel MJ, Vile RG, Dronca RS, Block MS. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. Front Immunol. 2023; 14:1279387 Epub 2023 Oct 31 View PubMed Hadadi A, Smith KE, Wan L, Brown JR, Russler G, Yantorni L, Caulfield S, Lafollette J, Moore M, Kucuk O, Carthon B, Nazha B, Liu Y, Bilen MA. Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. Urol Oncol. 2022 Jun; 40 (6):271.e9-271.e18 Epub 2022 Apr 22 View PubMed Solone XKV, Caldara AL, Wells B, Qiao H, Wade LR, Salerno JC, Helms KA, Smith KER, McMurry JL, Chrestensen CA. MAP kinases differentially bind and phosphorylate NOS3 via two unique NOS3 sites. FEBS Open Bio. 2022 May; 12 (5):1075-1086 Epub 2022 Mar 15 View PubMed Smith KER, Brown JT, Wan L, Liu Y, Russler G, Yantorni L, Caulfield S, Lafollette J, Moore M, Kucuk O, Carthon B, Nazha B, Bilen MA. Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. Oncologist. 2021 Nov; 26 (11):956-964 Epub 2021 June 29 View PubMed Barkin JL, Bloch JR, Smith KER, Telliard SN, McGreal A, Sikes C, Ezeamama A, Buoli M, Serati M, Bridges CC. Knowledge of and Attitudes Toward Perinatal Home Visiting in Women with High-Risk Pregnancies. J Midwifery Womens Health. 2021 Mar; 66 (2):227-232 Epub 2021 Feb 01 View PubMed Sahin IH, Kane SR, Brutcher E, Guadagno J, Smith KE, Wu C, Lesinski GB, Gunthel CJ, El-Rayes BF. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. JCO Oncol Pract. 2020 Jun; 16 (6):319-325 Epub 2020 Mar 11 View PubMed Rhoades KE, Hitron EE, Russler GA, Baumgarten DA, Bilen MA. Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review Journal of Immunotherapy and Precision Oncology. 2020; 3(1):23-26. Rhoades Smith KE, Bilen MA. A Review of Papillary Renal Cell Carcinoma and MET Inhibitors. Kidney Cancer. 2019 Nov 1; 3 (3):151-161 Epub 2019 Nov 01 View PubMed Rhoades K, Smith B, Honaker MD. Neoadjuvant Capecitabine Results in Similar Total Lymph Node Harvests as 5-Fluorouracil but an Increased Number of Lymph Nodes Containing Adenocarcinoma on Resection. Am Surg. 2018 Jul 1; 84 (7):e222-e224 View PubMed Rhoades K, Telliard S, Thomas TS, Barkin JL. Applications of and Barriers to Holistic Self-Care in a Low-Income, High-Risk Obstetric Population. Womens Health Issues. 2016 Nov - Dec; 26 (6):634-641 Epub 2016 Sept 30 View PubMed PST-20567885 Home Publications